Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenQuadfi booster immunogenicity and safety study in primed toddlers
2025-000002-42Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal A conjugate vaccine in meningococcal disease, sponsored by Sanofi. Primary endpoint: hSBA seroprotection rate.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2025-000002-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000002-42.